Madopar 250 Tablet contains a combination of Levodopa (200 mg) and Benserazide (50 mg), indicated primarily for the management of Parkinson’s disease and Parkinsonian syndromes. Levodopa serves as a precursor to dopamine, effectively replenishing diminished dopamine levels in the brain, which is a hallmark of Parkinson’s pathology. Benserazide, a peripheral dopa-decarboxylase inhibitor, prevents the peripheral conversion of Levodopa to dopamine, thereby enhancing its central nervous system availability and reducing peripheral side effects such as nausea and cardiovascular disturbances. Madopar 250 is utilized to alleviate motor symptoms including bradykinesia, rigidity, tremor, and postural instability. The combination therapy allows for a lower dose of Levodopa to achieve therapeutic effects while minimizing adverse reactions. Dosage and administration should be individualized based on clinical response and tolerability, with careful titration to optimize symptom control. Contraindications include hypersensitivity to components, narrow-angle glaucoma, and concurrent use with non-selective monoamine oxidase inhibitors. Common adverse effects may include dyskinesia, nausea, orthostatic hypotension, and hallucinations. Regular monitoring and follow-up are essential to adjust therapy and manage potential complications. Madopar 250 should be prescribed and used under medical supervision to ensure safe and effective treatment outcomes.